Pharmacological Approaches to Insomnia Management

Pharmacological management of insomnia encompasses a variety of agents that act on diverse neurochemical systems to facilitate sleep onset and maintenance. Traditional hypnotics include benzodiazepine receptor agonists and non-benzodiazepine ‘z-drugs’, which enhance γ-aminobutyric acid (GABA) signalling to promote sedation but carry risks of tolerance, dependence and next-day impairment. Melatonin receptor agonists and low-dose sedating antidepressants offer alternative mechanisms, with generally favourable safety but variable efficacy. More recently, orexin receptor antagonists have emerged as a novel class that targets the wake-promoting orexin system, demonstrating both efficacy and improved tolerability over longer treatment periods. Off-label use of antihistamines, antipsychotics and anticonvulsants remains common despite limited evidence and concerns regarding adverse effects. Comparative studies and clinical guidelines now emphasise a stepped-care approach that integrates these pharmacological options with behavioural interventions, underpinned by individual risk-benefit assessment and tailored to patient comorbidities and treatment goals. Emerging data on switching protocols and deprescribing strategies aim to reduce long-term dependence while maintaining symptom control.

Research from Nature Portfolio

Application of an advanced medical-ontology learning framework to clinical records has dramatically improved the detection of daytime impairment in insomnia, raising sensitivity from under 20 per cent to almost complete ascertainment. This data-driven approach reveals that benzodiazepine use significantly exacerbates daytime symptoms—a finding not captured by traditional coding—highlighting the importance of precise phenotyping for treatment evaluation and policy decisions.

A systematic analysis of randomised trials has elucidated the impact of trazodone on objective sleep architecture. Short-term administration increased total sleep time and deep non-rapid-eye-movement (N3) sleep, while reducing sleep latency, light-sleep stages and awakenings. However, the enhancement of slow-wave sleep was accompanied by a higher incidence of daytime drowsiness and appetite suppression, underlining the need to balance architectural benefits against tolerability in clinical use.

Pharmacological Approaches to Insomnia Management publication trend

The graph below shows the total number of articles in pharmacological approaches to insomnia management across all publications each year (not limited to Nature Index journals).

Technical terms

Dual orexin receptor antagonists (DORAs): Drugs that block both orexin receptor subtypes to promote sleep by inhibiting wake-promoting neuropeptides.
Benzodiazepine receptor agonists: Hypnotic agents binding to GABAA receptors to enhance inhibitory neurotransmission and induce sedation.
Polysomnography: A comprehensive sleep study recording physiological parameters (brain waves, eye movements, muscle activity) to assess sleep architecture.
Network meta-analysis: A statistical method that compares multiple treatments by combining direct and indirect evidence across randomised trials.
Sleep architecture: The structure and pattern of sleep stages (rapid-eye-movement and non-rapid-eye-movement sleep) over a sleep period.

References

1. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. Translational Psychiatry (2024).
2. Medical ontology learning framework to investigate daytime impairment in insomnia disorder and treatment effects. Communications Medicine (2025).
3. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research (2023).
4. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet (2022).
5. Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. International Journal of Molecular Sciences (2015).
6. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Scientific Reports (2022).
7. Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia. Journal of Clinical Medicine (2023).